📊 AKBA Key Takeaways
Is Akebia Therapeutics, Inc. (AKBA) a Good Investment?
Akebia demonstrates strong revenue growth (+47.5% YoY) and robust cash generation (FCF margin of 28.7%), but profitability remains challenged with negative net income despite positive operating income. The company maintains adequate liquidity with a 1.55x current ratio and substantial cash reserves ($184.8M), though elevated leverage (1.48x Debt/Equity) and negative returns on equity (-16.4%) signal ongoing operational pressures.
Akebia Therapeutics shows improving operating fundamentals, with positive operating income and strong free cash flow generation relative to revenue. However, the company still posted a net loss, carries meaningful leverage against a thin equity base, and lacks visible year-over-year trend data here, which limits conviction on the durability of the recent improvement.
Why Buy Akebia Therapeutics, Inc. Stock? AKBA Key Strengths
- Strong topline growth of 47.5% YoY indicating robust commercial execution
- Exceptional free cash flow generation at $67.7M with 28.7% FCF margin showing strong cash conversion
- Solid liquidity position with $184.8M cash and 1.55x current ratio providing financial flexibility
- Positive operating income and a 9.9% operating margin indicate the core business is currently generating operating profit
- Strong operating cash flow and free cash flow provide near-term financial flexibility, supported by $184.84M in cash
- Liquidity appears adequate with a 1.55x current ratio and 1.46x quick ratio
AKBA Stock Risks: Akebia Therapeutics, Inc. Investment Risks
- Persistent net losses (-$5.3M) and negative net margin (-2.3%) despite revenue growth suggests margin pressure or one-time charges
- Elevated leverage at 1.48x Debt/Equity with long-term debt of $48.2M relative to small equity base of $32.6M
- Negative returns on equity (-16.4%) and ROA (-1.4%) indicate inefficient asset utilization and value destruction for shareholders
- Net income remains negative, showing that profitability is not yet fully established
- Leverage is elevated relative to equity, with debt/equity of 1.48x and only $32.61M of stockholders equity
- Growth quality is harder to assess because year-over-year revenue and earnings trend data are not available in this snapshot
Key Metrics to Watch
- Path to net profitability and net margin expansion
- Debt reduction trajectory and leverage normalization
- Gross margin sustainability as revenue scales
- Sustained net income improvement and operating margin durability
- Cash burn or free cash flow consistency relative to liabilities and debt levels
Akebia Therapeutics, Inc. (AKBA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 28.7% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments.
AKBA Profit Margin, ROE & Profitability Analysis
AKBA vs Healthcare Sector: How Akebia Therapeutics, Inc. Compares
How Akebia Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Akebia Therapeutics, Inc. Stock Overvalued? AKBA Valuation Analysis 2026
Based on fundamental analysis, Akebia Therapeutics, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Akebia Therapeutics, Inc. Balance Sheet: AKBA Debt, Cash & Liquidity
AKBA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Akebia Therapeutics, Inc.'s revenue has declined by 29% over the 5-year period, indicating business contraction. The most recent EPS of $-0.28 indicates the company is currently unprofitable.
AKBA Revenue Growth, EPS Growth & YoY Performance
AKBA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $37.4M | $247.0K | $0.00 |
| Q2 2025 | $43.6M | $247.0K | $0.00 |
| Q1 2025 | $32.6M | $6.1M | $0.03 |
| Q3 2024 | $37.4M | -$8.6M | $-0.08 |
| Q2 2024 | $43.6M | -$8.6M | $-0.04 |
| Q1 2024 | $32.6M | -$18.0M | $-0.09 |
| Q3 2023 | $42.0M | -$11.2M | $-0.08 |
| Q2 2023 | $56.4M | -$11.2M | $-0.06 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Akebia Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
AKBA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Akebia Therapeutics, Inc. (CIK: 0001517022)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AKBA
What is the AI rating for AKBA?
Akebia Therapeutics, Inc. (AKBA) has a Combined AI Rating of HOLD from Claude (HOLD) and ChatGPT (HOLD) with 64% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AKBA's key strengths?
Claude: Strong topline growth of 47.5% YoY indicating robust commercial execution. Exceptional free cash flow generation at $67.7M with 28.7% FCF margin showing strong cash conversion. ChatGPT: Positive operating income and a 9.9% operating margin indicate the core business is currently generating operating profit. Strong operating cash flow and free cash flow provide near-term financial flexibility, supported by $184.84M in cash.
What are the risks of investing in AKBA?
Claude: Persistent net losses (-$5.3M) and negative net margin (-2.3%) despite revenue growth suggests margin pressure or one-time charges. Elevated leverage at 1.48x Debt/Equity with long-term debt of $48.2M relative to small equity base of $32.6M. ChatGPT: Net income remains negative, showing that profitability is not yet fully established. Leverage is elevated relative to equity, with debt/equity of 1.48x and only $32.61M of stockholders equity.
What is AKBA's revenue and growth?
Akebia Therapeutics, Inc. reported revenue of $236.2M.
Does AKBA pay dividends?
Akebia Therapeutics, Inc. does not currently pay dividends.
Where can I find AKBA SEC filings?
Official SEC filings for Akebia Therapeutics, Inc. (CIK: 0001517022) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AKBA's EPS?
Akebia Therapeutics, Inc. has a diluted EPS of $-0.02.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is AKBA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Akebia Therapeutics, Inc. has a HOLD rating with 64% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is AKBA stock overvalued or undervalued?
Valuation metrics for AKBA: ROE of -16.4% (sector avg: 15%), net margin of -2.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy AKBA stock in 2026?
Our dual AI analysis gives Akebia Therapeutics, Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is AKBA's free cash flow?
Akebia Therapeutics, Inc.'s operating cash flow is $68.0M, with capital expenditures of $291.0K. FCF margin is 28.7%.
How does AKBA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -2.3% (avg: 12%), ROE -16.4% (avg: 15%), current ratio 1.55 (avg: 2).